WO2024047483A1 - Arachidonic acid for preventing or decreasing post-operative bleeding - Google Patents
Arachidonic acid for preventing or decreasing post-operative bleeding Download PDFInfo
- Publication number
- WO2024047483A1 WO2024047483A1 PCT/IB2023/058406 IB2023058406W WO2024047483A1 WO 2024047483 A1 WO2024047483 A1 WO 2024047483A1 IB 2023058406 W IB2023058406 W IB 2023058406W WO 2024047483 A1 WO2024047483 A1 WO 2024047483A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bleeding
- arachidonic acid
- previous
- pharmaceutical composition
- post
- Prior art date
Links
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 title claims abstract description 190
- 235000021342 arachidonic acid Nutrition 0.000 title claims abstract description 93
- 229940114079 arachidonic acid Drugs 0.000 title claims abstract description 93
- 206010051077 Post procedural haemorrhage Diseases 0.000 title claims abstract description 60
- 230000003247 decreasing effect Effects 0.000 title claims description 9
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 230000007423 decrease Effects 0.000 claims abstract description 15
- 230000002612 cardiopulmonary effect Effects 0.000 claims abstract description 14
- 230000002265 prevention Effects 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 10
- 238000001356 surgical procedure Methods 0.000 claims description 46
- 230000002980 postoperative effect Effects 0.000 claims description 32
- 208000032843 Hemorrhage Diseases 0.000 claims description 24
- 208000034158 bleeding Diseases 0.000 claims description 20
- 230000000740 bleeding effect Effects 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 12
- 238000007675 cardiac surgery Methods 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000001772 blood platelet Anatomy 0.000 description 24
- 239000002207 metabolite Substances 0.000 description 20
- 230000009467 reduction Effects 0.000 description 18
- 206010073391 Platelet dysfunction Diseases 0.000 description 16
- FMNQRUKVXAQEAZ-JNRFBPFXSA-N (5z,8s,9r,10e,12s)-9,12-dihydroxy-8-[(1s)-1-hydroxy-3-oxopropyl]heptadeca-5,10-dienoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@@H](O)[C@H]([C@@H](O)CC=O)C\C=C/CCCC(O)=O FMNQRUKVXAQEAZ-JNRFBPFXSA-N 0.000 description 14
- XNRNNGPBEPRNAR-UHFFFAOYSA-N Thromboxane B2 Natural products CCCCCC(O)C=CC1OC(O)CC(O)C1CC=CCCCC(O)=O XNRNNGPBEPRNAR-UHFFFAOYSA-N 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 230000037361 pathway Effects 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 12
- 102000004889 Interleukin-6 Human genes 0.000 description 12
- 108090001005 Interleukin-6 Proteins 0.000 description 12
- 108010003541 Platelet Activating Factor Proteins 0.000 description 12
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 12
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 12
- 229940108924 conjugated linoleic acid Drugs 0.000 description 12
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 12
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 12
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 12
- NNDIXBJHNLFJJP-UHFFFAOYSA-N 20-Hydroxyeicosatetraenoic acid Chemical compound OCCCCCC=CCC=CCC=CCC=CCCCC(O)=O NNDIXBJHNLFJJP-UHFFFAOYSA-N 0.000 description 11
- 238000005259 measurement Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 8
- KSDMISMEMOGBFU-UHFFFAOYSA-N (all-Z)-7,10,13-Eicosatrienoic acid Natural products CCCCCCC=CCC=CCC=CCCCCCC(O)=O KSDMISMEMOGBFU-UHFFFAOYSA-N 0.000 description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000002596 correlated effect Effects 0.000 description 7
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 7
- 235000013922 glutamic acid Nutrition 0.000 description 7
- 239000004220 glutamic acid Substances 0.000 description 7
- 229940100601 interleukin-6 Drugs 0.000 description 7
- 238000002705 metabolomic analysis Methods 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 description 6
- 229940090949 docosahexaenoic acid Drugs 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 230000009469 supplementation Effects 0.000 description 6
- 102000003820 Lipoxygenases Human genes 0.000 description 5
- 108090000128 Lipoxygenases Proteins 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 230000001431 metabolomic effect Effects 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000000513 principal component analysis Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 3
- ZNHVWPKMFKADKW-LQWMCKPYSA-N 12(S)-HETE Chemical compound CCCCC\C=C/C[C@H](O)\C=C\C=C/C\C=C/CCCC(O)=O ZNHVWPKMFKADKW-LQWMCKPYSA-N 0.000 description 3
- -1 12-HETE Chemical class 0.000 description 3
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000037486 Postoperative Hemorrhage Diseases 0.000 description 3
- 201000011040 acute kidney failure Diseases 0.000 description 3
- 239000010836 blood and blood product Substances 0.000 description 3
- 229940125691 blood product Drugs 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002066 eicosanoids Chemical class 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000005399 mechanical ventilation Methods 0.000 description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000004885 tandem mass spectrometry Methods 0.000 description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000001765 aortic valve Anatomy 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- 229940116886 human interleukin-6 Drugs 0.000 description 2
- 238000003068 pathway analysis Methods 0.000 description 2
- 230000010118 platelet activation Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000008718 systemic inflammatory response Effects 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 208000026301 Postoperative Cognitive Complications Diseases 0.000 description 1
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010071090 Transfusion related complication Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 238000013176 antiplatelet therapy Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002283 elective surgery Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000004023 fresh frozen plasma Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 230000005980 lung dysfunction Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003634 thrombocyte concentrate Substances 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Definitions
- the present disclosure relates to arachidonic acid for use in the prevention or decrease of significant post-operative bleeding, preferably excessive post-operative bleeding, including when an extracorporeal circulation procedure as cardiopulmonary bypass is used. Furthermore, the present disclosure relates to compositions comprising arachidonic acid, namely ingestible and pharmaceutical compositions.
- Excessive post-operative bleeding also known as significant postoperative haemorrhage/ significant post-operative bleeding refers to an abnormal and potentially dangerous amount of bleeding that occurs after a surgical procedure. It occurs when blood vessels that were cut or manipulated during surgery fail to properly clot and seal, leading to prolonged or heavy bleeding at the surgical site. This can result in various complications and may necessitate further medical intervention to control the bleeding and prevent complications such as anemia, infection, or delayed wound healing. Excessive post-operative bleeding can vary in severity, ranging from minor oozing to more significant and lifethreatening hemorrhage.
- the risk of excessive bleeding can be influenced by factors such as the type of surgery performed, the patient's overall health, the use of certain medications (like blood thinners), and the surgical techniques employed. Surgeons take precautions to minimize the risk of excessive bleeding during surgery, but it remains an important consideration in post-operative care and management.
- PUFA Polyunsaturated fatty acids
- omega-6 fatty-acids have been associated with lower risk of cardiovascular events, especially due to anti-inflammatory proprieties [2,3], PUFA may regulate platelet activation enhancing endothelial repair, but current evidence is limited.
- AA Arachidonic acid
- AA-triggered aggregation is significantly decreased after CPB [1], but there is no information on the relation of peri-operative levels of AA and its metabolism on postoperative haemorrhage.
- AA concentration influences both normal cellular functions and the development of platelet dysfunction.
- AA metabolites act as local hormones and/ or signaling molecules in response to basal metabolism or upon regulation by immune response stimuli, such as the production of cytokines [24]
- CPB is associated with a significant systemic inflammatory response, with a complex and incompletely understood cross-talk between inflammation and coagulation [24,25].
- endothelial dysfunction during CPB induces the production of cytokines and platelet-induction factors [24,25].
- Some AA metabolites, such as 12-HETE have an important role in immune mediated platelet activation [23], Although not yet completely understood, 12-HETE potentiates dense granule secretion via NADPH-oxidase activation [23,24] and the activation of surface immunoreceptors [25],
- platelets after CPB have decreased levels of 12-HETE and a depressed activation of LOX activity, contributing to postoperative bleeding risk through an innate immunity-dependent perturb
- the present disclosure relates to arachidonic acid for use in the prevention or decrease of significant post-operative bleeding, preferably excessive post-operative bleeding, including when an extracorporeal circulation procedure as cardiopulmonary bypass is used. Furthermore, the present disclosure relates to compositions comprising arachidonic acid, namely ingestible and pharmaceutical compositions.
- the daily form consists of a tablet, suppository, ampoule or other device, comprising a definitive amount of arachidonic acid, the whole of which is intended to be administered as a single dose or in multiple parts.
- An aspect of the present disclosure relates to arachidonic acid or a pharmaceutically acceptable salt thereof for use in the prevention or decrease of significant post-operative bleeding; preferably excessive post-operative bleeding.
- the arachidonic acid or a pharmaceutically acceptable salt thereof may be use in the prevention or decrease of excessive post-operative cardiac surgery bleeding.
- the arachidonic acid or a pharmaceutically acceptable salt thereof may be use in surgery comprising extracorporeal circulation.
- the extracorporeal circulation is cardiopulmonary bypass.
- Another aspect of the present disclosure relates to a pharmaceutical composition comprising arachidonic acid or a pharmaceutically acceptable salts thereof in a therapeutically effective amount and a pharmaceutical acceptable carrier, adjuvant, excipient, or mixtures thereof for use in the prevention or decrease of significant post-operative bleeding; preferably excessive post-operative bleeding.
- the pharmaceutical composition is an oral pharmaceutical composition, to be administered before surgery, including urgent, emergent and elective surgery.
- the dosage amount ranges from 50 to 3600 mg/day; preferably 50 to 1800 mg/day; more preferably 50 to 800 mg/day; even more preferably 75 to 600 mg/day.
- the dosage amount ranges from 1000 to 3000 mg/day.
- the dosage amount is 1000 mg/day.
- the dosage amount is 3000 mg/day.
- the compound/composition of the present disclosure may be administrated before a surgical procedure.
- the compound/composition of the present disclosure may be administered every 24 hours at least in the 30 days preceding the surgical procedure; preferably at least in the 21 days preceding the surgical procedure; more preferably at least in the 7 days preceding the surgical procedure.
- the compound/composition of the present disclosure may be administered orally, in a dosage ranging from 50-3600 mg/day, at least 1 to 4 weeks before a surgical procedure.
- the dosage amount may be 1000 mg/day and the composition is administered every 24 hours in the 21 days preceding the surgical procedure.
- the dosage amount is 3000 mg/day and the composition is administered every 24 hours in the 21 days preceding the surgical procedure.
- the compound/composition of the present disclosure may be administered as a preoperative bolus (oral bolus), to be administered less than 24 hours before the surgical procedure; preferably less than 12h before the surgical procedure; or right before the surgery.
- a preoperative bolus oral bolus
- the amount of arachidonic acid in the preoperative bolus ranges from 50-3600 mg/single dose; preferably ranges from 900-3600 mg/single dose.
- the present disclosure relates to the use of an ingestible composition, capsule or tablet comprising the arachidonic acid or a suitable salt thereof, in pre-operative administration to prevent or decrease significant post-operative bleeding, preferably excessive post-operative bleeding.
- the administration is performed every 24 hours at least in the 7 days preceding the surgical procedure; preferably at least in the 21 days preceding the surgical procedure; more preferably at least in the 30 days preceding the surgical procedure.
- the daily form consists of a tablet, capsule, ampoule or other dosage form or device, comprising a definitive amount of 50-3600 mg.
- Another aspect of the present disclosure relates to the use of arachidonic acid or a pharmaceutically acceptable salt thereof or the composition herein described for the manufacture of a medicament for the prevention or decrease of significant post-operative bleeding; preferably excessive post-operative bleeding.
- Another aspect of the present disclosure relates to a method for preventing or decreasing significant post-operative bleeding; preferably excessive post-operative bleeding.
- the method comprising administering arachidonic acid or a pharmaceutically acceptable salt thereof or the composition herein described to the subject.
- Figure 1 Platelet count (A), variability in percentage (B), platelet mean volume (C) and platelet distribution width (D) of pre-operative and 6h and 24h postoperative patients. Values are presented in median with interquartile range.
- Figure 2 (A) Correlation of postoperative bleeding (mL) within the first postoperative 12h and preoperative quantification of arachidonic acid, with X presenting patients with higher levels of AA and non-significant postoperative bleeding and triangles presenting patients with low levels of AA and significant postoperative bleeding. Circles present arachidonic acid values and postoperative bleeding of the rest of the patients. (B) Preoperative arachidonic acid levels between patients with (white) or without (black) a significant postoperative bleeding (defined by postoperative chest tube blood loss of more than 600mL within 12 hours); C, Median postoperative chest tube blood within 12h according to arachidonic acid quantification.
- Figure 3 (A) Postoperative transfusion rate considering preoperative arachidonic acid quantification and the reduction in percentage at postoperative 6h. (B) Receiver operating characteristic (ROC) curve based on the preoperative arachidonic acid measurements and represented by an area under the curve (AUC) of 0.73 indicating a satisfactory predictive ability. (C) Correlation between human interleukin 6 (hlL6) levels and variability in arachidonic acid levels at 6h postoperative (percent change compared to preoperative levels).
- ROC Receiver operating characteristic
- FIG. 4 (A) HPLC-MS/MS quantification of arachidonic acid, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), conjugated linoleic acids (CLA), glutamic acid, 12- hydroxyeicosatetraenoic acid (12-HETE), platelet activating factor (PAF), 8,11,14-eicosatrienoic acid and thromboxane B2 (TxB2) in blood at 6h and 24h after surgery, comparing to preoperative quantification.
- EPA eicosapentaenoic acid
- DHA docosahexaenoic acid
- CLA conjugated linoleic acids
- glutamic acid glutamic acid
- 12-HETE 12- hydroxyeicosatetraenoic acid
- PAF platelet activating factor
- TxB2 thromboxane B2
- Figure 5A and 5B HPLC-MS/MS quantification of arachidonic acid, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), conjugated linoleic acids (CLA), glutamic acid, 12- hydroxyeicosatetraenoic acid (12-HETE), platelet activating factor (PAF), thromboxane B2 (TxB2) and 8,11,14-eicosatrienoic acid in blood at 6h and 24h after surgery, comparing to preoperative quantification, between patients with or without preoperative antiagreggation with acetylsalicylic acid; p ⁇ 0.05 (*); p ⁇ 0. 01 (**); p ⁇ 0.001 (***); p ⁇ 0.0001 (****).
- EPA eicosapentaenoic acid
- DHA docosahexaenoic acid
- CLA conjugated linoleic acids
- glutamic acid glutamic acid
- Figure 6A Relative reduction in levels of arachidonic acid, EPA, CLA, glutamic acid, PAF and TxB2 in blood at 6h and 24h after surgery, compared to preoperative levels (percent change), between patients with or without antiagreggation with acetylsalicylic acid. Values are presented in median with interquartile range. The following symbols were used in figures to indicate statistical significance: ns: non-significant; p ⁇ 0.05 (*); p ⁇ 0.01 (**); p ⁇ 0.001 (***); p ⁇ 0.0001 (****).
- Figure 6B Relative reduction in levels of DHA, 12-HETE, and 8,11,14-eicosatrienoic acid in blood at 6h and 24h after surgery, compared to preoperative levels (percent change), between patients with or without antiagreggation with acetylsalicylic acid. Values are presented in median with interquartile range. The following symbols were used in figures to indicate statistical significance: ns: non-significant; p ⁇ 0.05 (*); p ⁇ 0.01 (**); p ⁇ 0.001 (***); p ⁇ 0.0001 (****).
- Figure 7 (A) lnterleukin-6 (IL-6) levels of all patients; (B) IL-6 levels comparing patients with and without significant postoperative bleeding. The following symbols were used in figures to indicate statistical significance: ns: non-significant; p ⁇ 0.05 (*); p ⁇ 0.01 (**); p ⁇ 0.001 (***); p ⁇ 0.0001 (****).
- the present disclosure relates to arachidonic acid for use in the prevention or decrease of significant post-operative bleeding, preferably excessive post-operative bleeding including when an extracorporeal circulation procedure as cardiopulmonary bypass is used. Furthermore, the present disclosure relates to compositions comprising arachidonic acid, namely ingestible and pharmaceutical compositions.
- a clinical trial is performed to compare the supplementation of arachidonic acid versus placebo to test the potential of AA to reduce the risk of excessive postoperative bleeding in heart surgery patients. After pre-operative supplementation with arachidonic acid or placebo, postoperative bleeding, use of allogenic transfusions and platelet dysfunction is evaluated.
- the aortic valve replacement for inflammation (SVA-Study) registry is a study to characterize the inflammatory response after surgical aortic valve replacement (SAVR).
- SAVR surgical aortic valve replacement
- patients included were older than 18-years undergoing SAVR. Previous cardiac surgery, concomitant procedures, neoplasia and use of corticosteroids were exclusion criteria.
- Blood was collected from 33 patients before surgery, and 6h and 24h after surgery. Plasma was prepared and stored at -80°C. Medical records were assessed to obtain clinical data. All patients provided written informed consent and the study was approved by the Institutional Ethics Committee (Comissao Etica-CHLN, Ref.N. 9 23/18, April 2018), in accordance with Declaration of Helsinki and following STROBE guidelines.
- Postoperative chest tube output was quantified in the ICU hourly. Significant bleeding was considered when postoperative chest tube blood loss was above 600mL within 12h, as defined by the International Initiative on Haemostasis Management in Cardiac Surgery [14], The need for transfusion (platelet concentrate, packed red-blood cells, fresh frozen plasma and fibrinogen) was considered according to bleeding and/ or to correct aggregation and coagulation deficiencies [6,15],
- Extracted samples were thawed on ice, centrifuged for 2 min at 15,000xg, and diluted according to the different sample weight with 0.1% formic acid (RP, reversed-phase) or 50% acetonitrile (ACN) (HILIC, hydrophilic interaction chromatography). 2.5 mL of each diluted sample were pooled and used as a quality control (QC) sample.
- RP reversed-phase
- ACN acetonitrile
- Samples were randomly assigned into the autosampler and metabolites were separated on a SeQuant ZIC-pH ILIC HPLC column (Merck, 100 3 2.1 mm;5 mm) or a RP-column (Waters, ACQ.UITY UPLC HSS T3 150 3 2.1;1.8mm) with a flow rate of 100 mL/min delivered through an Ultimate 3000 HPLC system (Thermo-Fisher Scientific).
- the gradient ramp up time takes 25 min from 10% to 80%B in HILIC (A:ACN; B:25 mM ammonium bicarbonate(ABC) in water) and from 1% to 90% B in RP (A:0.1% FA in water;B:0.1% FA in ACN).
- Metabolites were ionized via electrospray ionization in polarity switching mode after HILIC separation and in positive polarity mode after RP separation.
- Sample spectra were acquired by data-dependent high-resolution tandem mass spectrometry on a Q-Exactive Focus(Thermo-Fisher Scientific). Ionization potential was set to +3.5/-3.0kV, the sheet gas flow was set to 20, and an auxiliary gas flow of 5 was used. Samples were analysed in a randomized fashion and QC samples were additionally measured in confirmation mode to obtain additional MS/MS spectra for identification. Obtained datasets were processed by compound discoverer 3.0(Thermo-Fisher Scientific).
- Cytokine concentrations were determined using human interleukin-6 (IL-6) kit (ELISA- MAXTM Deluxe Sets, BioLegend, San Diego, CA, USA), according to manufacturer's protocol and measured on a Tecan spectrophotometer plate-reader.
- IL-6 human interleukin-6
- Enrichment and pathway metabolomic analysis were performed using the MetaboAnalyst 5.0 tool [17], The following symbols were used in figures to indicate statistical significance: ns: non-significant; p ⁇ 0.05(*); p ⁇ 0.01(**); p ⁇ 0.001(***); p ⁇ 0.0001(****).
- a clinical trial is performed to compare the supplementation of arachidonic acid versus placebo to test the potential of AA to prevent excessive postoperative bleeding in heart surgery patients. It is observed that the administration of AA at a dose of 50-3600 mg/day in the 14-21 days preceding the surgical procedure induces a positive impact on patient's morbidity, reducing the risk of excessive postoperative bleeding and the use of allogenic transfusions and improving postoperative platelet dysfunction.
- a clinical trial is performed to compare the supplementation of arachidonic acid versus placebo to test the potential of AA to prevent excessive postoperative bleeding in heart surgery patients. It is observed that the administration of AA at a dose of 3000 mg/day in the 21 days preceding the surgical procedure induces a positive impact on patient's morbidity, reducing postoperative bleeding and the use of allogenic transfusions and improving postoperative platelet dysfunction.
- a clinical trial is performed to compare the supplementation of arachidonic acid versus placebo to test the potential of AA to prevent excessive postoperative bleeding risk in heart surgery patients. It is observed that the administration of AA at a dose of 1000 mg/day in the 14-21 days preceding the surgical procedure induces a positive impact on patient's morbidity, reducing postoperative bleeding and the use of allogenic transfusions and improving postoperative platelet dysfunction.
- AKI acute kidney injury
- BMI Body mass index
- LV left ventricular
- IQR interquartile range
- CPB cardiopulmonary bypass
- ICU intensive care unit
- Neurologic complication occurrence of stroke, delirium or postoperative cognitive dysfunction.
- Untargeted metabolomics data for the complete population recorded 8668 metabolic features for each plasma sample.
- Multivariate analysis was employed, mainly pattern recognition tools, such as principal component analysis (PCA), between patients with or without significant post-operative haemorrhage.
- PCA principal component analysis
- the PCA plot did not reveal a clear separation in the metabolic profile between both groups.
- it was performed a pairwise hypothesis test comparing pre and postoperative metabolite measurements at 24h. The pairwise hypothesis test identified statistically significant differences for 547 metabolites (p- value ⁇ 0.001). Using the 547-significant metabolites, an enrichment and pathway analysis were performed.
- AA eicosapentaenoic acid
- DHA docosahexaenoic acid
- CLA conjugated linoleic acids
- PAF platelet activating factor
- PAF concentrations (16.99x10 s IQR 14.05-18.8x10 s ) were significantly reduced at 6h (9.65x10 s IQR 7.56-11.37x10 s , p ⁇ 0.0001) and 24h (6.89x10 s IQR 5.86-8.16xlO s , p ⁇ 0.0001), compatible with the previously reported reduction of platelet activity after CPB. No significant changes were observed in thromboxane B2 concentrations at 6 and 24h.
- IQR interquartile range
- EPA eicosapentaenoic acid
- DHA docosahexaenoic acid
- CLA conjugated linoleic acids
- 12-HETE 12-hydroxyeicosatetraenoic acid
- PAF platelet activating factor
- TxB2 thromboxane B2; Pre-op: pre-operative; Post-op: postoperative
- the variation in the postoperative metabolite levels was not induced by the cardiopulmonary bypass reduction of platelet count, since platelet count at pre-operative, 6h and 24h was not correlated with metabolites measurement neither with the percentage of variation in the same timepoint.
- the absolute value and the variation of the metabolites were also not correlated with the variation in the MPV and PDW.
- the transfusion rate was also higher in patients with reduced pre-operative AA levels and with a post-operative reduction.
- patients with pre-op AA levels below 5xl0 8 ion count 42% required post-operative transfusion, versus 22% in patients with higher levels (p 0.418) ( Figure 3A.
- the necessity of hemodynamic support was higher, although not statistically significant, as well as mechanical ventilation for more than 6h and neurologic complications (Table 1).
- postoperative atrial fibrillation was more common in the group without significant bleeding.
- AA was later evaluated for predictive accuracy for identifying patients with an increased risk of significant bleeding. From the ROC curve, AA was identified as a predictor of postoperative significant bleeding with an AUC of 73.2% (Figure 3B).
- AA supplementation at a dose of 50-3600 mg/day in the days preceding the surgical procedure is safe and increases plasmatic levels of AA in a dosedependent manner
- ranges are included. Furthermore, it should be understood that unless otherwise indicated or otherwise evident from the context and/or understanding of a technical expert, the values which are expressed as ranges may assume any specific value within the ranges indicated in different achievements of the invention, at one tenth of the lower limit of the interval, unless the context clearly indicates the contrary. It should also be understood that, unless otherwise indicated or otherwise evident from the context and/or understanding of a technical expert, values expressed as range may assume any sub-range within the given range, where the limits of the sub-range are expressed with the same degree of precision as the tenth of the unit of the lower limit of the range.
- Kiefel V "Reactions induced by platelet transfusions," Transfus Med Hemother 2008; 35(5): 354-358
- van Hout FM Hogervorst EK, Rosseel P, et al.: Does a Platelet Transfusion Independently Affect Bleeding and Adverse Outcomes in Cardiac Surgery?," Anesthesiology 2017; 126(3):441-449
- Kawashima H Intake of arachidonic acid-containing lipids in adult humans: Dietary surveys and clinical trials, Lipids Health Dis 2019, 18(l):101
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Arachidonic acid, compositions and uses thereof The present disclosure relates to arachidonic acid for use in the prevention or decrease of significant post-operative bleeding, including when an extracorporeal circulation procedure as cardiopulmonary bypass is used. Furthermore, the present disclosure relates to compositions comprising arachidonic acid, namely ingestible and pharmaceutical compositions.
Description
ARACHIDONIC ACID FOR PREVENTING OR DECREASING POST-OPERATIVE BLEEDING
TECHNICAL FIELD
[0001] The present disclosure relates to arachidonic acid for use in the prevention or decrease of significant post-operative bleeding, preferably excessive post-operative bleeding, including when an extracorporeal circulation procedure as cardiopulmonary bypass is used. Furthermore, the present disclosure relates to compositions comprising arachidonic acid, namely ingestible and pharmaceutical compositions.
BACKGROUND
[0002] Excessive post-operative bleeding, also known as significant postoperative haemorrhage/ significant post-operative bleeding refers to an abnormal and potentially dangerous amount of bleeding that occurs after a surgical procedure. It occurs when blood vessels that were cut or manipulated during surgery fail to properly clot and seal, leading to prolonged or heavy bleeding at the surgical site. This can result in various complications and may necessitate further medical intervention to control the bleeding and prevent complications such as anemia, infection, or delayed wound healing. Excessive post-operative bleeding can vary in severity, ranging from minor oozing to more significant and lifethreatening hemorrhage. The risk of excessive bleeding can be influenced by factors such as the type of surgery performed, the patient's overall health, the use of certain medications (like blood thinners), and the surgical techniques employed. Surgeons take precautions to minimize the risk of excessive bleeding during surgery, but it remains an important consideration in post-operative care and management.
[0003] Excessive bleeding is a frequent complication after cardiac surgery with cardiopulmonary bypass (CPB), frequently requiring the use of allogenic blood products. Cardiac surgery accounts for 10-15% of transfusions in surgical patients in the United States yearly [1,2], and more than half of patients receive transfusion of blood products during hospital stay [3], Use of transfusions is not harmless, significantly impacting patients' outcome, increasing both morbidity and mortality, and healthcare costs [4], Moreover, postoperative bleeding is also associated with a higher rate of reoperation, which is independently associated with poorer outcomes [5],
[0004] CPB has a distinctive and significant contribution for the disruption of hemostasis in cardiac surgery [6,7], Platelet-function deficit is considered as the main CPB-induced hemostatic deficiency [8], CPB decreases the number of platelets by dilution, adhesion, destruction, and consumption [9] and this reduction is associated with excessive postoperative bleeding [9], Moreover, remaining platelets are functionally impaired, but mechanisms remain unclear [10], Even patients with a normal platelet count show higher prevalence of platelet dysfunction of unknown-cause [11], Although circulating platelets appear structurally normal, recovering within minutes after CPB, bleeding times increase and remain prolonged for several hours [12], Flow cytometry in whole-blood after CPB revealed no significant changes in platelet surface receptors [8] and few advances have been made in the field recently.
[0005] While lipid metabolism is essential for platelet activity and function [13], little is known regarding platelet metabolic changes associated with CPB-dysfunction.
[0006] Polyunsaturated fatty acids (PUFA), such as omega-6 fatty-acids, have been associated with lower risk of cardiovascular events, especially due to anti-inflammatory proprieties [2,3], PUFA may regulate platelet activation enhancing endothelial repair, but current evidence is limited. Additionally, it is well established that Arachidonic acid (AA) and its metabolites modulate platelet aggregation. AA-triggered aggregation is significantly decreased after CPB [1], but there is no information on the relation of peri-operative levels of AA and its metabolism on postoperative haemorrhage.
[0007] AA concentration influences both normal cellular functions and the development of platelet dysfunction. AA metabolites act as local hormones and/ or signaling molecules in response to basal metabolism or upon regulation by immune response stimuli, such as the production of cytokines [24], CPB is associated with a significant systemic inflammatory response, with a complex and incompletely understood cross-talk between inflammation and coagulation [24,25], It is known that endothelial dysfunction during CPB induces the production of cytokines and platelet-induction factors [24,25], Some AA metabolites, such as 12-HETE, have an important role in immune mediated platelet activation [23], Although not yet completely understood, 12-HETE potentiates dense granule secretion via NADPH-oxidase activation [23,24] and the activation of surface immunoreceptors [25], Moreover, platelets after CPB have decreased levels of 12-HETE and a depressed activation of LOX activity, contributing to postoperative bleeding risk through an innate immunity-dependent perturbation of coagulation factors function [30],
[0008] Although platelet transfusion is widely used to restore perioperative hemostasis, the decision is mainly empirical since there is no consensus regarding dose, trigger and efficacy [18], Moreover, platelet-transfusions are associated with several complications, including increased use of vasoactive drugs, extended mechanical ventilation, prolonged stay in the ICU and hospital, increased risk of postoperative infection and transfusion-related acute kidney injury [12,13], In fact, in a previous study, patients with postoperative significant bleeding had higher rates of hemodynamic support, mechanical ventilation for more than 6h and neurologic complications. Additionally, platelet transfusion is associated with considerable healthcare costs [21], The effort is now centered on reducing the use of blood products to decrease transfusion-related complications and costs. Therefore, it is essential to find new strategies able to reduce postoperative bleeding, leading to a positively impact on the patient's health and reducing the need of blood transfusions.
[0009] These facts are disclosed in order to illustrate the technical problem addressed by the present disclosure.
G EN ERAL DESCRIPTION
[0010] The present disclosure relates to arachidonic acid for use in the prevention or decrease of significant post-operative bleeding, preferably excessive post-operative bleeding, including when an extracorporeal circulation procedure as cardiopulmonary bypass is used. Furthermore, the present disclosure relates to compositions comprising arachidonic acid, namely ingestible and pharmaceutical compositions.
[0011] In an embodiment, the daily form consists of a tablet, suppository, ampoule or other device, comprising a definitive amount of arachidonic acid, the whole of which is intended to be administered as a single dose or in multiple parts.
[0012] An aspect of the present disclosure relates to arachidonic acid or a pharmaceutically acceptable salt thereof for use in the prevention or decrease of significant post-operative bleeding; preferably excessive post-operative bleeding.
[0013] In an embodiment, the arachidonic acid or a pharmaceutically acceptable salt thereof may be use in the prevention or decrease of excessive post-operative cardiac surgery bleeding.
[0014] In an embodiment, the arachidonic acid or a pharmaceutically acceptable salt thereof may be use in surgery comprising extracorporeal circulation.
[0015] In an embodiment the extracorporeal circulation is cardiopulmonary bypass.
[0016] Another aspect of the present disclosure relates to a pharmaceutical composition comprising arachidonic acid or a pharmaceutically acceptable salts thereof in a therapeutically effective amount and a pharmaceutical acceptable carrier, adjuvant, excipient, or mixtures thereof for use in the prevention or decrease of significant post-operative bleeding; preferably excessive post-operative bleeding.
[0017] In a preferred embodiment, the pharmaceutical composition is an oral pharmaceutical composition, to be administered before surgery, including urgent, emergent and elective surgery.
[0018] In an embodiment, the dosage amount ranges from 50 to 3600 mg/day; preferably 50 to 1800 mg/day; more preferably 50 to 800 mg/day; even more preferably 75 to 600 mg/day.
[0019] In a preferred embodiment, the dosage amount ranges from 1000 to 3000 mg/day.
[0020] In a preferred embodiment, the dosage amount is 1000 mg/day.
[0021] In another preferred embodiment, the dosage amount is 3000 mg/day.
[0022] In an embodiment the compound/composition of the present disclosure may be administrated before a surgical procedure. In an embodiment the compound/composition of the present disclosure may be administered every 24 hours at least in the 30 days preceding the surgical procedure; preferably at least in the 21 days preceding the surgical procedure; more preferably at least in the 7 days preceding the surgical procedure.
[0023] In an embodiment, the compound/composition of the present disclosure may be administered orally, in a dosage ranging from 50-3600 mg/day, at least 1 to 4 weeks before a surgical procedure.
[0024] In a preferred embodiment, the dosage amount may be 1000 mg/day and the composition is administered every 24 hours in the 21 days preceding the surgical procedure.
[0025] In another preferred embodiment, the dosage amount is 3000 mg/day and the composition is administered every 24 hours in the 21 days preceding the surgical procedure.
[0026] In an embodiment, the compound/composition of the present disclosure may be administered as a preoperative bolus (oral bolus), to be administered less than 24 hours before the surgical procedure; preferably less than 12h before the surgical procedure; or right before the surgery.
[0027] In an embodiment, the amount of arachidonic acid in the preoperative bolus ranges from 50-3600 mg/single dose; preferably ranges from 900-3600 mg/single dose.
[0028] In an embodiment, the present disclosure relates to the use of an ingestible composition, capsule or tablet comprising the arachidonic acid or a suitable salt thereof, in pre-operative administration to prevent or decrease significant post-operative bleeding, preferably excessive post-operative bleeding.
[0029] In an embodiment, the administration is performed every 24 hours at least in the 7 days preceding the surgical procedure; preferably at least in the 21 days preceding the surgical procedure; more preferably at least in the 30 days preceding the surgical procedure.
[0030] In an embodiment, the daily form consists of a tablet, capsule, ampoule or other dosage form or device, comprising a definitive amount of 50-3600 mg.
[0031] Another aspect of the present disclosure relates to the use of arachidonic acid or a pharmaceutically acceptable salt thereof or the composition herein described for the manufacture of a medicament for the prevention or decrease of significant post-operative bleeding; preferably excessive post-operative bleeding.
[0032] Another aspect of the present disclosure relates to a method for preventing or decreasing significant post-operative bleeding; preferably excessive post-operative bleeding. In a subject, the method comprising administering arachidonic acid or a pharmaceutically acceptable salt thereof or the composition herein described to the subject.
BRI EF DESCRI PTION OF THE DRAWINGS
[0033] The following figures provide preferred embodiments for illustrating the disclosure and should not be seen as limiting the scope of invention.
[0034] Figure 1: Platelet count (A), variability in percentage (B), platelet mean volume (C) and platelet distribution width (D) of pre-operative and 6h and 24h postoperative patients. Values are presented in median with interquartile range.
[0035] Figure 2: (A) Correlation of postoperative bleeding (mL) within the first postoperative 12h and preoperative quantification of arachidonic acid, with X presenting patients with higher levels of AA and non-significant postoperative bleeding and triangles presenting patients with low levels of AA and significant postoperative bleeding. Circles present arachidonic acid values and postoperative bleeding of the rest of the patients. (B) Preoperative arachidonic acid levels between patients with (white) or without (black) a significant postoperative bleeding (defined by postoperative chest tube blood loss of more than 600mL within 12 hours); C, Median postoperative chest tube blood within 12h according to arachidonic acid quantification.
[0036] Figure 3: (A) Postoperative transfusion rate considering preoperative arachidonic acid quantification and the reduction in percentage at postoperative 6h. (B) Receiver operating characteristic (ROC) curve based on the preoperative arachidonic acid measurements and represented by an area under the curve (AUC) of 0.73 indicating a satisfactory predictive ability. (C) Correlation between human interleukin 6 (hlL6) levels and variability in arachidonic acid levels at 6h postoperative (percent change compared to preoperative levels).
[0037] Figure 4: (A) HPLC-MS/MS quantification of arachidonic acid, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), conjugated linoleic acids (CLA), glutamic acid, 12- hydroxyeicosatetraenoic acid (12-HETE), platelet activating factor (PAF), 8,11,14-eicosatrienoic acid and thromboxane B2 (TxB2) in blood at 6h and 24h after surgery, comparing to preoperative quantification. (B) Relative reduction in levels of arachidonic acid, EPA, DHA, CLA, glutamic acid, 12-HETE, PAF, 8,11,14-eicosatrienoic acid and TxB2 in blood at 6h and 24h after surgery, compared to preoperative levels (percent change). Values are presented in median with interquartile range. The following symbols were used in figures to indicate statistical significance: ns: non-significant; p<0.05 (*); p<0.01 (**); p<0.001 (***); p<0.0001 (****).
[0038] Figure 5A and 5B: HPLC-MS/MS quantification of arachidonic acid, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), conjugated linoleic acids (CLA), glutamic acid, 12- hydroxyeicosatetraenoic acid (12-HETE), platelet activating factor (PAF), thromboxane B2 (TxB2) and 8,11,14-eicosatrienoic acid in blood at 6h and 24h after surgery, comparing to preoperative quantification, between patients with or without preoperative antiagreggation with acetylsalicylic acid; p<0.05 (*); p<0. 01 (**); p<0.001 (***); p<0.0001 (****).
[0039] Figure 6A: Relative reduction in levels of arachidonic acid, EPA, CLA, glutamic acid, PAF and TxB2 in blood at 6h and 24h after surgery, compared to preoperative levels (percent change), between patients with or without antiagreggation with acetylsalicylic acid. Values are presented in median with interquartile range. The following symbols were used in figures to indicate statistical significance: ns: non-significant; p<0.05 (*); p<0.01 (**); p<0.001 (***); p<0.0001 (****).
[0040] Figure 6B: Relative reduction in levels of DHA, 12-HETE, and 8,11,14-eicosatrienoic acid in blood at 6h and 24h after surgery, compared to preoperative levels (percent change), between patients with or without antiagreggation with acetylsalicylic acid. Values are presented in median with interquartile range. The following symbols were used in figures to indicate statistical significance: ns: non-significant; p<0.05 (*); p<0.01 (**); p<0.001 (***); p<0.0001 (****).
[0041] Figure 7: (A) lnterleukin-6 (IL-6) levels of all patients; (B) IL-6 levels comparing patients with and without significant postoperative bleeding. The following symbols were used in figures to indicate statistical significance: ns: non-significant; p<0.05 (*); p<0.01 (**); p<0.001 (***); p<0.0001 (****).
DETAILED DESCRIPTION
[0042] The present disclosure relates to arachidonic acid for use in the prevention or decrease of significant post-operative bleeding, preferably excessive post-operative bleeding including when an extracorporeal circulation procedure as cardiopulmonary bypass is used. Furthermore, the present disclosure relates to compositions comprising arachidonic acid, namely ingestible and pharmaceutical compositions.
[0043] To explore the possible contribution of metabolic perturbations for platelet dysfunction after cardiac surgery with CPB, it was performed an untargeted metabolomic analysis using high-performance liquid chromatography-tandem mass spectrometry (HPLC- MS/MS) to identify specific metabolic signatures that contribute to platelet dysfunction after CPB.
Materials and Methods
Porcine model of cardiopulmonary-induced platelet dysfunction.
[0044] The confirmation of the biological impact of the administration of arachidonic acid is performed with a porcine model of cardiopulmonary-induced platelet dysfunction. Establishing a swine model of cardiopulmonary bypass, we compare a group with previous administration of arachidonic acid with a placebo group, collecting blood postoperatively to measure platelet dysfunction.
Clinical trial
[0045] A clinical trial is performed to compare the supplementation of arachidonic acid versus placebo to test the potential of AA to reduce the risk of excessive postoperative bleeding in heart surgery patients. After pre-operative supplementation with arachidonic acid or placebo, postoperative bleeding, use of allogenic transfusions and platelet dysfunction is evaluated.
Study Population
[0046] The aortic valve replacement for inflammation (SVA-Study) registry is a study to characterize the inflammatory response after surgical aortic valve replacement (SAVR). In an
embodiment, patients included were older than 18-years undergoing SAVR. Previous cardiac surgery, concomitant procedures, neoplasia and use of corticosteroids were exclusion criteria. Blood was collected from 33 patients before surgery, and 6h and 24h after surgery. Plasma was prepared and stored at -80°C. Medical records were assessed to obtain clinical data. All patients provided written informed consent and the study was approved by the Institutional Ethics Committee (Comissao Etica-CHLN, Ref.N.923/18, April 2018), in accordance with Declaration of Helsinki and following STROBE guidelines.
Classification of Hemorrhage
[0047] Postoperative chest tube output was quantified in the ICU hourly. Significant bleeding was considered when postoperative chest tube blood loss was above 600mL within 12h, as defined by the International Initiative on Haemostasis Management in Cardiac Surgery [14], The need for transfusion (platelet concentrate, packed red-blood cells, fresh frozen plasma and fibrinogen) was considered according to bleeding and/ or to correct aggregation and coagulation deficiencies [6,15],
Untargeted metabolomics
[0048] An untargeted metabolomics study was performed for supporting information. After generation of blood plasma, proteins were removed by adding 400pL of a methanol/ ethanol mixture(4:l,v/v) to lOOpI of plasma, followed by vigorous vortex shaking for 5 minutes at room-temperature and centrifugating at 4000xg-10min at 4°C. The supernatant was collected, transferred to an Eppendorf, shock frozen with liquid nitrogen, and stored at -80°C until analysis. Extracted samples were thawed on ice, centrifuged for 2 min at 15,000xg, and diluted according to the different sample weight with 0.1% formic acid (RP, reversed-phase) or 50% acetonitrile (ACN) (HILIC, hydrophilic interaction chromatography). 2.5 mL of each diluted sample were pooled and used as a quality control (QC) sample. Samples were randomly assigned into the autosampler and metabolites were separated on a SeQuant ZIC-pH ILIC HPLC column (Merck, 100 3 2.1 mm;5 mm) or a RP-column (Waters, ACQ.UITY UPLC HSS T3 150 3 2.1;1.8mm) with a flow rate of 100 mL/min delivered through an Ultimate 3000 HPLC system (Thermo-Fisher Scientific). The gradient ramp up time takes 25 min from 10% to 80%B in HILIC (A:ACN; B:25 mM ammonium bicarbonate(ABC) in water) and from 1% to 90% B in RP (A:0.1% FA in water;B:0.1% FA in ACN). Metabolites were ionized via electrospray ionization in polarity switching mode after HILIC separation and in positive polarity mode after RP separation. Sample spectra were acquired by data-dependent high-resolution tandem mass spectrometry on a Q-Exactive Focus(Thermo-Fisher Scientific). Ionization potential was set to +3.5/-3.0kV,
the sheet gas flow was set to 20, and an auxiliary gas flow of 5 was used. Samples were analysed in a randomized fashion and QC samples were additionally measured in confirmation mode to obtain additional MS/MS spectra for identification. Obtained datasets were processed by compound discoverer 3.0(Thermo-Fisher Scientific). Compound annotation was conducted by searching the mzCloud database with a mass accuracy of 3 ppm for precursor masses and 10 ppm for fragment ion masses as well as ChemSpider with a mass accuracy of 3 ppm using BioCyc, Human Metabolome Database, KEGG, MassBank and MetaboLights as databases.
Cytokine measurement
[0049] Cytokine concentrations were determined using human interleukin-6 (IL-6) kit (ELISA- MAXTM Deluxe Sets, BioLegend, San Diego, CA, USA), according to manufacturer's protocol and measured on a Tecan spectrophotometer plate-reader.
Statistical Analysis
[0050] Principal Component Analysis was performed with R [16], using the basic package "stats". Remaining statistical analysis was performed using GraphPad Prim 9.0(GraphPad Software). Continuous variables are presented with median with interquartile range and were analyzed using Wilcoxon matched-pairs signed rank test for paired samples and Wilcoxon rank sum test for non-paired samples, adjusted to FDR. Pairwise comparison was performed between pre and postoperative samples. The Bonferroni correction was performed to reduce the chances of obtaining false-positive results (type I errors). Categorical variables are reported in percentage or frequency and were analyzed using chi-squared test. For correlation we used the Spearman's rank-order correlation. Predictive models were performed using logistic regression. Enrichment and pathway metabolomic analysis were performed using the MetaboAnalyst 5.0 tool [17], The following symbols were used in figures to indicate statistical significance: ns: non-significant; p<0.05(*); p<0.01(**); p<0.001(***); p<0.0001(****).
Results
Porcine model of cardiopulmonary-induced platelet dysfunction.
[0051] The confirmation of the biological impact of the administration of arachidonic acid in a dosage ranging from 50-3600 mg is performed with a porcine model of cardiopulmonary- induced platelet dysfunction. It is observed that the administration of AA induces a positive impact on post-cardiopulmonary bypass platelet dysfunction, improving platelet function and reducing postoperative cardiopulmonary-related bleeding.
Clinical trial
Example A
[0052] A clinical trial is performed to compare the supplementation of arachidonic acid versus placebo to test the potential of AA to prevent excessive postoperative bleeding in heart surgery patients. It is observed that the administration of AA at a dose of 50-3600 mg/day in the 14-21 days preceding the surgical procedure induces a positive impact on patient's morbidity, reducing the risk of excessive postoperative bleeding and the use of allogenic transfusions and improving postoperative platelet dysfunction.
Example B
[0053] A clinical trial is performed to compare the supplementation of arachidonic acid versus placebo to test the potential of AA to prevent excessive postoperative bleeding in heart surgery patients. It is observed that the administration of AA at a dose of 3000 mg/day in the 21 days preceding the surgical procedure induces a positive impact on patient's morbidity, reducing postoperative bleeding and the use of allogenic transfusions and improving postoperative platelet dysfunction.
Example C
[0054] A clinical trial is performed to compare the supplementation of arachidonic acid versus placebo to test the potential of AA to prevent excessive postoperative bleeding risk in heart surgery patients. It is observed that the administration of AA at a dose of 1000 mg/day in the 14-21 days preceding the surgical procedure induces a positive impact on patient's morbidity, reducing postoperative bleeding and the use of allogenic transfusions and improving postoperative platelet dysfunction.
[0055] It was surprisingly found that the preoperative administration of AA is safe and effective to reduce platelet dysfunction after cardiac surgery with CPB, reducing postoperative bleeding and the necessity of transfusion. The reduction of allogenic transfusions is associated with lower intensive care unit and hospital lengths of stay, and less renal and pulmonary dysfunction, leading to lower healthcare-related costs.
Untargeted metabolomics
[0056] Patient's demographic and clinical characteristics are detailed in Table 1. No differences were observed between the two groups (significant bleeding and no significant bleeding) regarding age, gender, comorbidities, left ventricle function and median Euroscorell.
Table 1. Surgery and postoperative Data
AKI: acute kidney injury; BMI: Body mass index; LV: left ventricular; IQR: interquartile range; CPB: cardiopulmonary bypass; ICU: intensive care unit
Haemodynamic support: use of vasopressors to maintain adequate perfusion, without the necessity of mechanical support
Neurologic complication: occurrence of stroke, delirium or postoperative cognitive dysfunction.
[0057] Untargeted metabolomics data for the complete population recorded 8668 metabolic features for each plasma sample. Multivariate analysis was employed, mainly pattern recognition tools, such as principal component analysis (PCA), between patients with or without significant post-operative haemorrhage. The PCA plot did not reveal a clear separation in the metabolic profile between both groups. I Then, it was performed a pairwise hypothesis test comparing pre and postoperative metabolite measurements at 24h. The pairwise hypothesis test identified statistically significant differences for 547 metabolites (p- value<0.001). Using the 547-significant metabolites, an enrichment and pathway analysis were performed. From the top 30 pathways identified in our analysis (Table 2), it is identified a platelet-related signature, characterized by an overrepresentation of changes in one known fatty acid metabolism pathway (arachidonic acid [AA] pathway) involved in platelet function. The list of the studied metabolites, associated with the identified pathway, is presented in Table 3.
Table 2. Pathway analysis from the comparison between pre-operative and postoperative metabolites.
Table 3. Arachidonic acid related metabolites identified by untargeted metabolomics
[0058] It was evaluated the concentrations of the 9 features associated with the AA pathway: AA, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), conjugated linoleic acids (CLA), platelet activating factor (PAF) (as part of the upstream activation of AA metabolism), 8,11,14- eicosatrienoic acid (eicosanoids pathway), 12-HETE and glutamic acid (lipoxygenase pathway) and thromboxane B2(TxB2) [cyclooxygenase pathway],
[0059] Considering all patients with measurements for the three time-points, levels of AA in the preoperative were 5.93xl08 [ion counts - all the values are ion counts (area) linearly proportional to the actual concentration of the metabolite] (IQR 4.4xl08-7.4xl08). Although absolute measurements remained stable at 6h-5.6xlO8(IQR 4.3xl08-7.1xl08,p=0.55), they were significantly decreased at 24h 4.17xlO8(IQR 3.08xl08-5.5xl08,p<0.0001) (Figure 4 A).
[0060] Revealing a similar pattern, levels of EPA (7.98xl07 IQR 5.15-12.67xl07) and DHA(5.23xlO8 IQR 4.5-8.06xl08) remained stable at 6h (8.19xl07 IQR 4.92-10.8xl07, p=0.247 and 5.43xl08 IQR 3.57-7.34xl08,p=0.505, respectively) but significantly decreased at 24h (4.27xl07 IQR 2.95-6.86xl07,p<0.0001 and 3.57xl08 IQR 2.54-5.41xl08,p<0.0001, respectively) [Supplementary Figure 2A], CLA increased at 6h (3.1xl08 IQR 1.8-4.91xl08, p=0.059), and returned to near basal concentrations at 24h (2.3xl08 IQRl.36-3.9xlO8, p=0.972) [Figure 4A],
[0061] AA metabolites derived from the lipoxygenase pathway, such as glutamic acid (20.59xl08 IQR 15.97-25.02) and 12-HETE (1.45xl07 IQR 0.92-1.98), had a significant reduction in the absolute measurements at 6h (13.37x10s IQR 9.97-17.03xl08, p<0.0001 and 1.17xl07 IQR 0.77-1.54xl07, p<0.0001, respectively), and 24h (13.03x10s IQR 8.58-16.56xl0s, p<0.001, and 1.13xl07 IQR 0.88-1.63xl07, p<0.0001, respectively) [Figure 4A],
[0062] PAF concentrations (16.99x10s IQR 14.05-18.8x10s) were significantly reduced at 6h (9.65x10s IQR 7.56-11.37x10s, p<0.0001) and 24h (6.89x10s IQR 5.86-8.16xlOs, p<0.0001), compatible with the previously reported reduction of platelet activity after CPB. No significant changes were observed in thromboxane B2 concentrations at 6 and 24h.
[0063] Interestingly, the concentrations of 8,11,14-eicosatrienoic acid (1.83x10s IQR 1.37- 2.32x10s) were unchanged at 6h (2.06x10s IQR 1.51-2.38x10s, p=0.271) but reduced at 24h (1.24x10s IQR 1-1.53x10s, p<0.001).
[0064] Because two postoperative measurements were tested for the nine metabolites, a Bonferroni-adjusted significance level of 0.00278 was calculated to account for the increased possibility of type-1 error.
[0065] To evaluate if the variation of the metabolites followed a similar trend than the absolute value, it was calculated the change in the metabolites measurements at 6h and 24h (percentage of change comparing to pre-operatory levels) (Figure 4B and Table 4). Although a high percentage of patients had a pronounced reduction at 6h, median reduction of AA, EPA and DHA was not significant at 6h. However, levels were significantly reduced at 24h. On the other hand, CLA had an increase at 6h with a non-significant variation at 24h. Glutamic acid and 12-HETE had a similar pattern of reduction both at 6h and 24h. Although PAF measurement were reduced at 6h, the reduction was even more pronounced at 24h. In contrast, TxB2 values were more reduced at 6h than at 24h. 8,11,14-eicosatrienoic acid showed a particular pattern, with a median increase of 19.4% (-15;44.8), significantly decreasing at 24h.
Table 4. Metabolites absolute values and relative change in percentage compared to preoperative levels
IQR: interquartile range; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; CLA: conjugated linoleic acids; 12-HETE: 12-hydroxyeicosatetraenoic acid; PAF: platelet activating factor; TxB2: thromboxane B2; Pre-op: pre-operative; Post-op: postoperative
Platelet count and morphology and antiplatelet therapy
[0066] In the population of the present study, platelet count decreased after surgery (Figure 1A), with a median -32.8% (-39.5;-28.8) at 6h and -28.5% (-35;-18.2) at 24h (Figure IB). The reduction was consistent within all patients (Figure IB), and was not correlated to any comorbidity or the use of anticoagulation and/ or anti-aggregation. Consistent with previous reports, mean platelet volume (MPV) was also reduced at 6h and 24h (Figure 1C). However, platelet distribution width (PDW) remained stable at all times (Figure ID).
[0067] Importantly, the variation in the postoperative metabolite levels was not induced by the cardiopulmonary bypass reduction of platelet count, since platelet count at pre-operative, 6h and 24h was not correlated with metabolites measurement neither with the percentage of variation in the same timepoint. The absolute value and the variation of the metabolites were also not correlated with the variation in the MPV and PDW.
[0068] Considering that a substantial percentage of patients were medicated with platelet inhibitors (AAT), it was assessed if preoperative AAT influenced preoperative levels and their variation. None of our patients was taking non-steroidal anti-inflammatory drugs and 45.5% (15 patients) were taking acetylsalicylic acid (ASA) [Table 1], Patients taking ASA had similar levels of the studied metabolites in the preoperative (Figure 5). No significant differences were observed in any of the analyzed compounds in absolute levels for each timepoint, and for the percentage of reduction at 6h and 24h (Figure 5-6).
Arachidonic acid signature and postoperative bleeding
[0069] Based on the AA metabolic signature observed, it was tested whether pre-operatory levels of AA were associated with post-operative bleeding. It was surprisingly found that levels of preoperative AA were inversely correlated with postoperative chest tube blood loss at 24h (R=-0.3957;*p=0.03) (Figure 2A). In contrast, the postoperative blood loss was not correlated with platelet count in the preoperative (R=-0.04, p=0.815), at 6h (R=-0.098, p=0.597) or at 24h (R=-0.06,p=0.741). Considering patients with a significant postoperative blood-loss (at least 600mL in the first 12h after surgery), the preoperative levels of AA were considerably lower (4.8xl08 vs 6.8xl08, *p=0.032) (Figure 2B). The subjects with low levels of pre-operatory AA (first quartile of no significant bleeding) had increased risk of postoperative bleeding with a relative risk (RR) 2.8 [95% confidence interval (Cl) 1.19-6.68] and odds ratio (OR) 7 (95% Cl 1.35-30.25), *p=0.045. Among individuals with preoperative levels of AA below 5xl08, the postoperative blood loss (600cc IQR 325-600 vs 350cc IQR 300-400, *p=0.029) were substantially higher (Figure 2C).
[0070] Moreover, the transfusion rate was also higher in patients with reduced pre-operative AA levels and with a post-operative reduction. In patients with pre-op AA levels below 5xl08 ion count 42% required post-operative transfusion, versus 22% in patients with higher levels (p=0.418) (Figure 3A. Additionally, patients with reduced levels of AA at 6h also had a higher rate of transfusion, compared to those with unchanged or increased values (40% vs 28%, p=0.489)(Figure 3A], Regarding other outcomes in patients with postoperative bleeding, the necessity of hemodynamic support was higher, although not statistically significant, as well as
mechanical ventilation for more than 6h and neurologic complications (Table 1). Interestingly, postoperative atrial fibrillation was more common in the group without significant bleeding.
[0071] AA was later evaluated for predictive accuracy for identifying patients with an increased risk of significant bleeding. From the ROC curve, AA was identified as a predictor of postoperative significant bleeding with an AUC of 73.2% (Figure 3B).
[0072] As CPB is associated with a systemic inflammatory response, it was also measured IL-6 levels (Figure 7A) and correlated them with postoperative AA variability (Figure 3C). It was observed a strong correlation between IL-6 levels and the AA variability(r=- 0.602,***p=0.0004), suggesting a possible role of the inflammatory setting in AA metabolism perturbation. Curiously, IL6 levels were lower in patients with significant postoperative bleeding Figure 7B).
[0073] It was observed that IL6 concentrations 6h after surgery are strongly correlated with the variability in AA levels in our patients, suggesting that inflammation plays an essential role in postoperative AA dysfunction. Interestingly, not all the pathways of AA-activation may have the same relevance in post-operative bleeding. We have seen that levels of TxB2 remain stable, consistent with previous studies that have also reported that TxB2 plasma levels one hour and 24h after the operation had returned to preoperative values [12], Moreover, although concentrations of metabolites from both eicosanoids and lipoxygenase pathways were reduced at 6h and 24h, the reduction remains approximately the same at 6h and 24h, while the reduction of the metabolite representing lipoxygenase is much pronounced at 24h. Thus, while cyclooxygenase pathway may remain unchanged, eicosanoid and lipoxygenase pathways may be differently disrupted. Curiously, patients with significant postoperative bleeding had lower levels of IL6, especially beginning 12h post-operative. It has been documented that AA can induce the release of IL-6 from inflammatory cells, inducing the production of acute-phase proteins to balance some of the detrimental effects of AA metabolites in shock [31], IL-6 augments platelet count and function and the thrombotic potential of IL6 is greater than its fibrinolytic effect in hemorrhage, especially in the early stages of bleeding [32], The fact that IL6 levels are lower in patients with significant hemorrhage is a possible consequence of the AA metabolism perturbation.
[0074] The present disclosure shows that preoperative AA administration is effective in reducing platelet dysfunction after cardiac surgery with CPB, reducing postoperative bleeding and the necessity of transfusion. AA supplementation at a dose of 50-3600 mg/day in the days
preceding the surgical procedure is safe and increases plasmatic levels of AA in a dosedependent manner
[0075] The term "comprising" whenever used in this document is intended to indicate the presence of stated features, integers, steps, components, but not to preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.
[0076] The disclosure should not be seen in any way restricted to the embodiments described and a person with ordinary skill in the art will foresee many possibilities to modifications thereof. The above described embodiments are combinable.
[0077] Where ranges are provided, the range limits are included. Furthermore, it should be understood that unless otherwise indicated or otherwise evident from the context and/or understanding of a technical expert, the values which are expressed as ranges may assume any specific value within the ranges indicated in different achievements of the invention, at one tenth of the lower limit of the interval, unless the context clearly indicates the contrary. It should also be understood that, unless otherwise indicated or otherwise evident from the context and/or understanding of a technical expert, values expressed as range may assume any sub-range within the given range, where the limits of the sub-range are expressed with the same degree of precision as the tenth of the unit of the lower limit of the range.
[0078] The following dependent claims further set out particular embodiments of the disclosure.
References
[1] Robich MP, Koch C, Johnston DR et al.: Trends in blood utilization in United States cardiac surgical patients," Transfusion 2015; 55(4):805-814
[2] Sullivan MT, Cotton R, Read EJ, et al: Blood collection and transfusion in the United States in 2001," Transfusion 2007, 47(3):385-394
[3] Bennett-Guerrero E, Zhao Y, O'Brien SM, et al.: Variation in Use of Blood Transfusion in Coronary Artery Bypass Graft Surgery, JAMA 2010; 304(14):1568-75
[4] LaPar DJ, Crosby IK, Ailawadi G, et al.: Blood product conservation is associated with improved outcomes and reduced costs after cardiac surgery, J Thorac Cardiovasc Surg 2012, 145(3):796-804
[5] Vivacqua A, Kosh CG, Yousuf AM, et al.: Morbidity of bleeding after cardiac surgery: Is it blood transfusion, reoperation for bleeding, or both?, Ann Thorac Surg 2011, 91(6): 1780- 1790
[6] Boer C, Meesters Ml, Milojevic M, et al: 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery, J Cardiothorac Vase Anesth 2018; 32(l):88-120
[7] Alghamdi AA, Davis A, Brister S, et al: Development and validation of Transfusion Risk Understanding Scoring Tool (TRUST) to stratify cardiac surgery patients according to their blood transfusion needs," Transfusion 2006; 46(7):1120-1129
[8] Kestin AS, Valeri CR, Khuri SF, et al: The Platelet Function Defect of Cardiopulmonary Bypass, Blood 1993, 82(l):107-17
[9] Ichikawa J, Osada Y, Kodaka M, et al: Association between platelet count and postoperative blood loss in patients undergoing cardiac surgery with cardiopulmonary bypass and fresh frozen plasma administration guided by thromboelastometry," Circulation Journal 2018; 82(3): 677-683
[10] Kjellberg G, Holm M, Lindvall G, et al: Platelet function analysed by ROTEM platelet in cardiac surgery after cardiopulmonary bypass and platelet transfusion," Transfusion Medicine 2020, 30(5): 369-376
[11] Lopes CT, Brunori E, Cavalcante A: Factors associated with excessive bleeding after cardiac surgery: A prospective cohort study, Heart and Lung 2016; 45(1): 64-69. e2
[12] Zilla P, Fasol R, Groscurth P, et al: Blood platelets in cardiopulmonary bypass operations. Recovery occurs after initial stimulation, rather than continual activation, J Thorac Cardiovasc Surgery 1989, 97(3): 379-388
[13] Paes AM, Gaspar RS, Fuentes E, et al: Lipid metabolism and signaling in platelet function; Adv Exp Med Biol 2019, 1127:97-115
[14] Dyke C, Aronson S, Dietrich W, et al: Universal definition of perioperative bleeding in adult cardiac surgery, J Thorac Cardiovasc Surgery 2014, 147(5):1458-1463.el
[15] Tibi P, McClure RS, Huang J, et al.: STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management; Ann Thorac Surg 2021; 112(3): 981-1004
[16] R Core Team, "R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria." Vienna, Austria, 2021.
[17] Pang Z, Chong J, Zhou G, et al.: MetaboAnalyst 5.0: Narrowing the gap between raw spectra and functional insights, Nucleic Acids Res 2021, 49(W1):W388-W396
[18] Levy JH, Rossaint R, Zacharowski K, et al: What is the evidence for platelet transfusion in perioperative settings?, Vox Sanguinis 2017; 112(8):704-712
[19] Kiefel V: "Reactions induced by platelet transfusions," Transfus Med Hemother 2008; 35(5): 354-358
[20] van Hout FM, Hogervorst EK, Rosseel P, et al.: Does a Platelet Transfusion Independently Affect Bleeding and Adverse Outcomes in Cardiac Surgery?," Anesthesiology 2017; 126(3):441-449
[21] Shander A, Hofmann A, Gombotz H: Estimating the cost of blood: past, present, and future directions, Best Practice and Research: Clinical Anaesthesiology 2007; 21(2):271-289
[22] Pirillo A, Catapano: Omega-3 for Cardiovascular Diseases: Where Do We Stand after REDUCE-IT and STRENGTH?; Circulation 2021; 144(3): 183-185
[23] Wu JH, Lemaitre RN, King IB, et al.: Circulating omega-6 polyunsaturated fatty acids and total and cause-specific mortality: The cardiovascular health study; Circulation 2014; 130(15):1245-1253
[24] Serhan C, Oliw E: Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways; J Clin Invest 2001; 107(12):1481-1489
[25] Laffey JG, Boylan J F, Cheng D: The Systemic Inflammatory Response to Cardiac Surgery Implications for the Anesthesiologist; Anesthesiology 2002; 97(l):215-52
[26] Paparella D, Brister SJ, Buchanan MR: Coagulation disorders of cardiopulmonary bypass: A review, Intensive Care Medicine 2004, 30(10): 1873-1881
[27] Yeung J, Apopa PL, Vesci J, et al.: 12-lipoxygenase activity plays an important role in PAR4 and GPVI-mediated platelet reactivity, Thromb Haemost 2013, 110(3): 569-581
[28] Contursi A, Schiavone S, Dovizio M, et al.: Platelets induce free and phospholipid- esterified 12-hydroxyeicosatetraenoic acid generation in colon cancer cells by delivering 12- lipoxygenase, J Lipid Res 2021, 62:100109
[29] Yeung J, Tourdot B, Fernandez-Perez P, et al.: Platelet 12-LOX is essential for FcgRI la- mediated platelet activation Key Points; Blood 2014, 124(14):2271-2279
[30] Slatter DA, Percy CL, Allen-Redpath K, et al.: Enzymatically oxidized phospholipids restore thrombin generation in coagulation factor deficiencies, JCI insight 2018, 3(6):e98459
[31] Holladay CS, Wright RM, Spangelo BL: Arachidonic acid stimulates interleukin-6 release from rat peritoneal macrophages in vitro: Evidence for a prostacyclin-dependent mechanism, Prostaglandins, Leukotrienes and Essential Fatty Acids 1993, 49(6): 915-922
[32] Katsuyama I, Mayumi T, Kohanawa M, et al: Bleeding induced interleukin-6 decreases blood loss via activation of coagulation, Shock 1999 ll(2):87-92
[33] Kawashima H: Intake of arachidonic acid-containing lipids in adult humans: Dietary surveys and clinical trials, Lipids Health Dis 2019, 18(l):101
Claims
C L A I M S Arachidonic acid or a pharmaceutically acceptable salt thereof for use in the prevention or decrease of significant post-operative bleeding; preferably excessive post-operative bleeding. Arachidonic acid for use according to the previous claim for use in the prevention or decrease of post-operative cardiac surgery bleeding. Arachidonic acid for use according to any of the previous claims wherein the surgery comprises extracorporeal circulation. Arachidonic acid for use according to any of the previous claims wherein the extracorporeal circulation is cardiopulmonary bypass. Pharmaceutical composition comprising arachidonic acid or a salt thereof in a therapeutically effective amount and a pharmaceutical acceptable carrier, adjuvant, excipient or mixtures thereof for use in the prevention or decrease of significant postoperative bleeding; preferably excessive post-operative bleeding. Pharmaceutical composition comprising arachidonic acid or a pharmaceutically acceptable salt thereof for use as described in any of the previous claims 1-4. Pharmaceutical composition for use according to the previous claim wherein said composition is an oral pharmaceutical composition; preferably a tablet or a capsule. Pharmaceutical composition for use according to any of the previous claims 5-7 wherein the dosage amount ranges from 50 to 3600 mg/day. Pharmaceutical composition for use according to the previous claim wherein the dosage amount is 1000 mg/day. Pharmaceutical composition for use according to the previous claim 8 wherein the dosage amount is 3000 mg/day.
Pharmaceutical composition for use according to the previous claim 8 wherein the dosage amount ranges from 900 to 3600 mg/day. Pharmaceutical composition for use according to any of the previous claims 5-11, wherein said composition is for administration before a surgical procedure. Pharmaceutical composition for use according to the previous claim for administration every 24 hours at least in the 30 days preceding the surgical procedure; preferably at least in the 21 days preceding the surgical procedure; more preferably at least in the 7 days preceding the surgical procedure. Pharmaceutical composition for use according to the previous claim wherein the dosage amount is 1000 mg/day and the composition is administered every 24 hours in the 21 days preceding the surgical procedure. Pharmaceutical composition for use according to the previous claim 13 wherein the dosage amount is 3000 mg/day and the composition is administered every 24 hours in the 21 days preceding the surgical procedure. The use of arachidonic acid or a pharmaceutically acceptable salt thereof or the composition according to any of the previous claims 5-15 for the manufacture of a medicament for the prevention or decrease of significant post-operative bleeding; preferably excessive post-operative bleeding. A method for preventing or decreasing significant post-operative bleeding, preferably excessive post-operative bleeding, in a subject, the method comprising administering arachidonic acid or a pharmaceutically acceptable salt thereof or the composition according to any of the previous claims 5-15 to the subject.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PT11817322 | 2022-08-29 | ||
PT118173 | 2022-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024047483A1 true WO2024047483A1 (en) | 2024-03-07 |
Family
ID=88204266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2023/058406 WO2024047483A1 (en) | 2022-08-29 | 2023-08-24 | Arachidonic acid for preventing or decreasing post-operative bleeding |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024047483A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060088573A1 (en) * | 2003-10-29 | 2006-04-27 | Suntory Limited | Composition having action preventing or alleviating symtoms or diseases due to aging of blood vessels |
WO2007017240A2 (en) * | 2005-08-10 | 2007-02-15 | Tiberio Bruzzese | Composition of n-3 fatty acids having high concentration of epa and/or dha and containing n-6 fatty acids |
US20140271610A1 (en) * | 2013-03-12 | 2014-09-18 | Orthovita, Inc. | Collagen and alginate-based formulations for hemostasis |
WO2019014595A1 (en) * | 2017-07-13 | 2019-01-17 | Thrombo Therapeutics, Inc. | Compositions and methods for wound closure |
-
2023
- 2023-08-24 WO PCT/IB2023/058406 patent/WO2024047483A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060088573A1 (en) * | 2003-10-29 | 2006-04-27 | Suntory Limited | Composition having action preventing or alleviating symtoms or diseases due to aging of blood vessels |
WO2007017240A2 (en) * | 2005-08-10 | 2007-02-15 | Tiberio Bruzzese | Composition of n-3 fatty acids having high concentration of epa and/or dha and containing n-6 fatty acids |
US20140271610A1 (en) * | 2013-03-12 | 2014-09-18 | Orthovita, Inc. | Collagen and alginate-based formulations for hemostasis |
WO2019014595A1 (en) * | 2017-07-13 | 2019-01-17 | Thrombo Therapeutics, Inc. | Compositions and methods for wound closure |
Non-Patent Citations (34)
Title |
---|
ALGHAMDI AADAVIS ABRISTER S ET AL.: "Development and validation of Transfusion Risk Understanding Scoring Tool (TRUST) to stratify cardiac surgery patients according to their blood transfusion needs", TRANSFUSION, vol. 46, no. 7, 2006, pages 1120 - 1129, XP055197479, DOI: 10.1111/j.1537-2995.2006.00860.x |
BENNETT-GUERRERO EZHAO YO'BRIEN SM ET AL.: "Variation in Use of Blood Transfusion in Coronary Artery Bypass Graft Surgery", JAMA, vol. 304, no. 14, 2010, pages 1568 - 75 |
BOER CMEESTERS MIMILOJEVIC M ET AL.: "EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery", J CARDIOTHORAC VASC ANESTH, vol. 32, no. 1, 2018, pages 88 - 120, XP085376784, DOI: 10.1053/j.jvca.2017.06.026 |
CONTURSI ASCHIAVONE SDOVIZIO M ET AL.: "Platelets induce free and phospholipid-esterified 12-hydroxyeicosatetraenoic acid generation in colon cancer cells by delivering 12-lipoxygenase", J LIPID RES, vol. 62, 2021, pages 100109 |
DYKE CARONSON SDIETRICH W ET AL.: "Universal definition of perioperative bleeding in adult cardiac surgery", J THORAC CARDIOVASC SURGERY, vol. 147, no. 5, 2014, pages 1458 - 1463 |
HOLLADAY CSWRIGHT RMSPANGELO BL: "Arachidonic acid stimulates interleukin-6 release from rat peritoneal macrophages in vitro: Evidence for a prostacyclin-dependent mechanism, Prostaglandins", LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, vol. 49, no. 6, 1993, pages 915 - 922, XP026329584, DOI: 10.1016/0952-3278(93)90176-W |
ICHIKAWA JOSADA YKODAKA M ET AL.: "Association between platelet count and postoperative blood loss in patients undergoing cardiac surgery with cardiopulmonary bypass and fresh frozen plasma administration guided by thromboelastometry", CIRCULATION JOURNAL, vol. 82, no. 3, 2018, pages 677 - 683 |
KATSUYAMA IMAYUMI TKOHANAWA M ET AL.: "Bleeding induced interleukin-6 decreases blood loss via activation of coagulation", SHOCK, vol. 11, no. 2, 1999, pages 87 - 92 |
KAWASHIMA H: "Intake of arachidonic acid-containing lipids in adult humans: Dietary surveys and clinical trials", LIPIDS HEALTH DIS, vol. 18, no. 1, 2019, pages 101 |
KESTIN ASVALERI CRKHURI SF ET AL.: "The Platelet Function Defect of Cardiopulmonary Bypass", BLOOD, vol. 82, no. 1, 1993, pages 107 - 17 |
KIEFEL V: "Reactions induced by platelet transfusions", TRANSFUS MED HEMOTHER, vol. 35, no. 5, 2008, pages 354 - 358 |
KJELLBERG GHOLM MLINDVALL G ET AL.: "Platelet function analysed by ROTEM platelet in cardiac surgery after cardiopulmonary bypass and platelet transfusion", TRANSFUSION MEDICINE, vol. 30, no. 5, 2020, pages 369 - 376 |
LAFFEY JGBOYLAN JFCHENG D: "The Systemic Inflammatory Response to Cardiac Surgery Implications for the Anesthesiologist", ANESTHESIOLOGY, vol. 97, no. 1, 2002, pages 215 - 52 |
LAPAR DJCROSBY IKAILAWADI G ET AL.: "Blood product conservation is associated with improved outcomes and reduced costs after cardiac surgery", J THORAC CARDIOVASC SURG, vol. 145, no. 3, 2012, pages 796 - 804, XP028979722, DOI: 10.1016/j.jtcvs.2012.12.041 |
LEVY JHROSSAINT RZACHAROWSKI K ET AL.: "What is the evidence for platelet transfusion in perioperative settings?", VOX SANGUINIS, vol. 112, no. 8, 2017, pages 704 - 712 |
LOPES CTBRUNORI ECAVALCANTE A: "Factors associated with excessive bleeding after cardiac surgery: A prospective cohort study", HEART AND LUNG, vol. 45, no. 1, 2016, pages 64 - 69 |
PAES AMGASPAR RSFUENTES E ET AL.: "Lipid metabolism and signaling in platelet function", ADV EXP MED BIOL, vol. 1127, 2019, pages 97 - 115 |
PANG ZCHONG JZHOU G ET AL.: "MetaboAnalyst 5.0: Narrowing the gap between raw spectra and functional insights", NUCLEIC ACIDS RES, vol. 49, no. W1, 2021, pages W388 - W396 |
PAPARELLA DBRISTER SJBUCHANAN MR: "Coagulation disorders of cardiopulmonary bypass: A review", INTENSIVE CARE MEDICINE, vol. 30, no. 10, 2004, pages 1873 - 1881, XP055466252, DOI: 10.1007/s00134-004-2388-0 |
PIRILLO A, CATAPANO: "Omega-3 for Cardiovascular Diseases: Where Do We Stand after REDUCE-IT and STRENGTH?", CIRCULATION, vol. 144, no. 3, 2021, pages 183 - 185 |
ROBICH MPKOCH CJOHNSTON DR ET AL.: "Trends in blood utilization in United States cardiac surgical patients", TRANSFUSION, vol. 55, no. 4, 2015, pages 805 - 814 |
SERHAN COLIW E: "Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways", J CLIN INVEST, vol. 107, no. 12, 2001, pages 1481 - 1489 |
SHANDER AHOFMANN AGOMBOTZ H: "Estimating the cost of blood: past, present, and future directions", BEST PRACTICE AND RESEARCH: CLINICAL ANAESTHESIOLOGY, vol. 21, no. 2, 2007, pages 271 - 289, XP022111522 |
SLATTER DAPERCY CLALLEN-REDPATH K ET AL.: "Enzymatically oxidized phospholipids restore thrombin generation in coagulation factor deficiencies", JCI INSIGHT, vol. 3, no. 6, 2018, pages e98459 |
SULLIVAN MTCOTTON RREAD EJ ET AL.: "Blood collection and transfusion in the United States in 2001", TRANSFUSION, vol. 47, no. 3, 2007, pages 385 - 394 |
TERWINDT L E ET AL: "Patient blood management in the cardiac surgical setting: An updated overview", TRANSFUSION AND APHERESIS SCIENCE, ELSEVIER SCIENCE, LONDON, GB, vol. 58, no. 4, 25 June 2019 (2019-06-25), pages 397 - 407, XP085772897, ISSN: 1473-0502, [retrieved on 20190625], DOI: 10.1016/J.TRANSCI.2019.06.015 * |
TIBI PMCCLURE RSHUANG J ET AL.: "STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management", ANN THORAC SURG, vol. 112, no. 3, 2021, pages 981 - 1004 |
VAN HOUT FMHOGERVORST EKROSSEEL P ET AL.: "Does a Platelet Transfusion Independently Affect Bleeding and Adverse Outcomes in Cardiac Surgery?", ANESTHESIOLOGY, vol. 126, no. 3, 2017, pages 441 - 449 |
VELHO TIAGO R. ET AL: "Role of Omega-6 Fatty Acid Metabolism in Cardiac Surgery Postoperative Bleeding Risk", CRITICAL CARE EXPLORATIONS, vol. 4, no. 10, 1 October 2022 (2022-10-01), pages e0763, XP093102080, DOI: 10.1097/CCE.0000000000000763 * |
VIVACQUA AKOSH CGYOUSUF AM ET AL.: "Morbidity of bleeding after cardiac surgery: Is it blood transfusion, reoperation for bleeding, or both?", ANN THORAC SURG, vol. 91, no. 6, 2011, pages 1780 - 1790, XP028219271, DOI: 10.1016/j.athoracsur.2011.03.105 |
WU JHLEMAITRE RNKING IB ET AL.: "Circulating omega-6 polyunsaturated fatty acids and total and cause-specific mortality: The cardiovascular health study", CIRCULATION, vol. 130, no. 15, 2014, pages 1245 - 1253 |
YEUNG JAPOPA PLVESCI J ET AL.: "12-lipoxygenase activity plays an important role in PAR4 and GPVI-mediated platelet reactivity", THROMB HAEMOST, vol. 110, no. 3, 2013, pages 569 - 581 |
YEUNG JTOURDOT BFERNANDEZ-PEREZ P ET AL.: "Platelet 12-LOX is essential for FcgRlla-mediated platelet activation Key Points", BLOOD, vol. 124, no. 14, 2014, pages 2271 - 2279 |
ZILLA PFASOL RGROSCURTH P ET AL.: "Blood platelets in cardiopulmonary bypass operations. Recovery occurs after initial stimulation, rather than continual activation", J THORAC CARDIOVASC SURGERY, vol. 97, no. 3, 1989, pages 379 - 388 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Trimethylamine‐N‐Oxide induces vascular inflammation by activating the NLRP3 inflammasome through the SIRT3‐SOD2‐mtROS signaling pathway | |
Shyamsundar et al. | Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers | |
Kaiafa et al. | Anemia and stroke: Where do we stand? | |
Guan et al. | Cerebrolysin ameliorates focal cerebral ischemia injury through neuroinflammatory inhibition via CREB/PGC-1α pathway | |
Oliveira | Novel serologic markers of cardiovascular risk | |
Yang et al. | Study on urine metabolic profiling and pathogenesis of hyperlipidemia | |
Wang et al. | Dexmedetomidine suppresses sevoflurane anesthesia-induced neuroinflammation through activation of the PI3K/Akt/mTOR pathway | |
Lili et al. | A preliminary study of the effects of ulinastatin on early postoperative cognition function in patients undergoing abdominal surgery | |
MXPA04001555A (en) | Tocopherol enriched compositions and amelioration of inflammatory symptoms. | |
Wu et al. | Acrolein aggravates secondary brain injury after intracerebral hemorrhage through Drp1-mediated mitochondrial oxidative damage in mice | |
Kücükakin et al. | No effect of melatonin to modify surgical-stress response after major vascular surgery: a randomised placebo-controlled trial | |
US20200215014A1 (en) | Methods For Assessing Risk Of Cardiovascular Disease And Methods And Compounds For Use In Treating Or Preventing Cardiovascular Disease | |
Ma et al. | Annexin A1 bioactive peptide promotes resolution of neuroinflammation in a rat model of exsanguinating cardiac arrest treated by emergency preservation and resuscitation | |
Karolczak et al. | Aldosterone modulates blood homocysteine and cholesterol in coronary artery disease patients–a possible impact on atherothrombosis? | |
Zhou et al. | Preoperative intravenous flurbiprofen reduces postoperative pain and inflammatory cytokines in elderly patients after hip arthroplasty | |
Xie et al. | Effect of dexmedetomidine on perioperative inflammation and lung protection in elderly patients undergoing radical resection of lung cancer | |
Qu et al. | Impact of low-dose urokinase in peritoneal dialysis on serum oxidative stress, nitric oxide and endothelin in cerebral infarction complicated with uremia | |
Burg et al. | Livedoid vasculopathy–A diagnostic and therapeutic challenge | |
Shao et al. | Simvastatin suppresses lung inflammatory response in a rat cardiopulmonary bypass model | |
Liu et al. | Curcumin alleviates aβ42-induced neuronal metabolic dysfunction via the thrb/SIRT3 Axis and improves cognition in APPTG mice | |
Manchanda et al. | Metabolic reprogramming and reliance in human skin wound healing | |
Zhang et al. | Central nervous system inflammation induced by lipopolysaccharide up-regulates hepatic hepcidin expression by activating the IL-6/JAK2/STAT3 pathway in mice | |
Shi et al. | Application of different anesthetic methods in coronary artery bypass grafting and the effect on postoperative outcome | |
WO2024047483A1 (en) | Arachidonic acid for preventing or decreasing post-operative bleeding | |
Jeremy et al. | Sustained increases of plasma homocysteine, copper, and serum ceruloplasmin after coronary artery bypass grafting |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23777352 Country of ref document: EP Kind code of ref document: A1 |